公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2021 | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens | Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU ; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. | Breast Cancer Research and Treatment | 10 | 10 | |
2020 | Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma | Sangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG ; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A. | Journal of Hepatology | 223 | 207 | |
2021 | Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study | Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG | Liver Cancer | 62 | 49 | |
2020 | Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG ; Rimassa L. | Future Oncology | 50 | 49 | |
2020 | Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma | Kelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG ; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K. | Advances in Therapy | 31 | 28 | |
2019 | Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552](S0168827819303009)(10.1016/j.jhep.2019.05.014) | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. | Journal of Hepatology | 1 | 9 | |
2020 | Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial | Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU | JAMA Oncology | 697 | 646 | |
2017 | Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study | ANN-LII CHENG ; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; KUN-HUEI YEH ; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. | Clinical Colorectal Cancer | 21 | 19 | |
2019 | First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma | Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN ; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. | Cancer Discovery | 154 | 136 | |
2021 | Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240 | Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG ; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M. | Cancer | 13 | 17 | |
2012 | Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012 | Ku G.; Tan I.B.; Yau T.; Boku N.; Laohavinij S.; ANN-LII CHENG ; Kang Y.-K.; de Lima Lopes G. | The Lancet Oncology | 66 | 61 | |
2022 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | Zhu A.X.; Abbas A.R.; de Galarreta M.R.; Guan Y.; Lu S.; Koeppen H.; Zhang W.; CHIH-HUNG HSU ; He A.R.; Ryoo B.-Y.; Yau T.; Kaseb A.O.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Wang Y. | Nature Medicine | 108 | 115 | |
2020 | Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial | Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU ; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators | Journal of Clinical Oncology | 360 | 311 | |
2019 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. | Journal of Hepatology | 168 | 154 | |
2017 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. | The Lancet | 3010 | 2816 | |
2020 | Novel systemic therapy for hepatocellular carcinoma | Dong Y.; TSUNG-HAO LIU ; Yau T.; CHIUN HSU | Hepatology International | 13 | 11 | |
2019 | An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma | El Dika I.; Lim H.Y.; Yong W.P.; CHIA-CHI LIN ; Yoon J.-H.; Modiano M.; Freilich B.; Choi H.J.; Chao T.-Y.; Kelley R.K.; Brown J.; Knox J.; Ryoo B.-Y.; Yau T.; Abou-Alfa G.K. | Oncologist | 75 | 59 | |
2021 | Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial | Kudo M.; Lim H.Y.; ANN-LII CHENG ; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y. | Liver Cancer | 30 | 26 | |
2020 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial | Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG ; KEYnote-240 investigators | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 1188 | 1028 | |
2011 | Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics | Yau T.; PEI-JER CHEN ; Chan P.; Curtis C.M.; Murphy P.S.; Suttle A.B.; Gauvin J.; Hodge J.P.; Dar M.M.; Poon R.T. | Clinical Cancer Research | 67 | 63 | |